Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report

• Main Authors: Jon Washburn (Author), David S. Millington (Author)
• Format: Book
• Published: MDPI AG, 2020-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/ijns6040078; 2409-515X
• Keywords: newborn screening; digital microfluidics; Hurler syndrome; alpha-<span style="font-variant: small-caps">L</span>-iduronidase assay; dried blood spots; Pediatrics; RJ1-570
• Source: International Journal of Neonatal Screening, Vol 6, Iss 4, p 78 (2020)

Newborn screening (NBS) for mucopolysaccharidosis type I (MPS I, Hurler syndrome) is currently conducted in about two-fifths of the NBS programs in the United States and in a few other countries. Screening is performed by measurement of residual activity of the enzyme <i>alpha</i>-<span style="font-variant: small-caps;">l</span>-iduronidase in dried blood spots using either tandem mass spectrometry or digital microfluidic fluorometry (DMF). In this article, we focus on the development and practical experience of using DMF to screen for MPS I in the USA. By means of their responses to a questionnaire, we determined for each responding program that is screening for MPS I using DMF the screen positive rate, follow-up methods, and classification of confirmed cases as either severe or attenuated. Overall, the results show that at the time of reporting, over 1.3 million newborns in the US were screened for MPS I using DMF, 2094 (0.173%) of whom were screen positive. Of these, severe MPS I was confirmed in five cases, attenuated MPS I was confirmed in two cases, and undetermined phenotype was reported in one case. We conclude that DMF is an effective and economical method to screen for MPS I and recommend second-tier testing owing to high screen positive rates. Preliminary results of NBS for MPS II and MPS III using DMF are discussed.